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Aicardi-Goutie`res syndrome (AGS), a hereditary
autoimmune disease, clinically and biochemically
overlaps with systemic lupus erythematosus (SLE)
and, like SLE, is characterized by spontaneous type
I interferon (IFN) production. The finding that defects
of intracellular nucleases cause AGS led to the
concept that intracellular accumulation of nucleic
acids triggers inappropriate production of type I
IFN and autoimmunity. AGS can also be caused
by defects of SAMHD1, a 30 exonuclease and deoxy-
nucleotide (dNTP) triphosphohydrolase. Human
SAMHD1 is an HIV-1 restriction factor that hy-
drolyzes dNTPs and decreases their concentra-
tion below the levels required for retroviral reverse
transcription. We show in gene-targeted mice that
also mouse SAMHD1 reduces cellular dNTP con-
centrations and restricts retroviral replication in
lymphocytes, macrophages, and dendritic cells.
Importantly, the absence of SAMHD1 triggered IFN-
b-dependent transcriptional upregulation of type I
IFN-inducible genes in various cell types indicative
of spontaneous IFN production. SAMHD1-deficient
mice may be instrumental for elucidating the mecha-nisms that trigger pathogenic type I IFN responses in
AGS and SLE.INTRODUCTION
Systemic lupus erythematosus (SLE) is characterized by a
chronic type I interferon (IFN) response, which is considered to
play a central role in the breakdown of self-tolerance (Bancher-
eau and Pascual, 2006; Pascual et al., 2006; Ro¨nnblom et al.,
2011). Defective clearance of chromatin-containing cellular
debris resulting in uncontrolled activation of sensors of the innate
immune system by endogenous nucleic acids has been exten-
sively discussed as a mechanism that triggers a pathogenic
IFN response. Aicardi-Goutie`res syndrome (AGS) is character-
ized by early-onset leukencephalopathy resembling congenital
viral infection with intracerebral calcifications and cerebrospinal
fluid lymphocytosis (Crow and Rehwinkel, 2009). Importantly,
AGS clinically overlaps with SLE and, like SLE, features uncon-
trolled production of type I IFN, although to date, no viral infec-
tion has been causally linked to AGS (Rice et al., 2007b). AGS
can be caused by mutations in one of four intracellular enzymes
involved in nucleic acid metabolism, including 30 repair exonu-
clease (TREX)1 (Crow et al., 2006a), a 30 exonuclease with sub-
strate preference for single-stranded DNA (ssDNA); RNase H2
(Crow et al., 2006b), which cleaves RNA:DNA hybrids; adenosine
deaminase acting on RNA 1 (ADAR1) (Rice et al., 2012), an RNACell Reports 4, 689–696, August 29, 2013 ª2013 The Authors 689
editing enzyme; and the deoxynucleotide triphosphohydrolase
SAM domain and HD domain 1 (SAMHD1) (Rice et al., 2009).
The finding that a rare monogenic form of lupus can also be
caused by mutations in TREX1 (Lee-Kirsch et al., 2007a; Rice
et al., 2007a) or SAMHD1 (Ravenscroft et al., 2011), as well as
the identification of SLE patients carrying mutations in TREX1
(Lee-Kirsch et al., 2007b) and a report of the coexistence of
AGS and SLE in a patient with mutated SAMHD1 (Ramantani
et al., 2011), further underpinned the tight pathogenetic relation-
ship between AGS and SLE.
Trex1/mice spontaneously develop autoimmunemultiorgan
inflammation, which can be rescued by additional inactivation of
the type I IFN system, demonstrating the critical pathogenetic
role of the IFN response (Morita et al., 2004; Stetson et al.,
2008; Gall et al., 2012). These findings led to a new concept of
autoimmunity caused by defects of nucleic acid metabolism
resulting in intracellular accumulation of endogenous nucleic
acids, which in turn trigger a type I IFN response (Stetson et al.,
2008). Short ssDNA species originating during DNA replication
(Yang et al., 2007) or replication intermediates of endogenous
retroelements (Stetson et al., 2008) were proposed to be respon-
sible for activation of the IFN system in Trex1/ mice. Loss of
ADAR1 in mice is embryonically lethal and Adar1/ mouse
embryos, like Trex1/ mice, display spontaneous production
of type I IFN (Hartner et al., 2009). Mice deficient for RNase H2
accumulate ribonucleotides in genomic DNA, resulting in a
spontaneous DNA damage response (Reijns et al., 2012; Hiller
et al., 2012). The relevance of this observation for the induction
of autoimmunity in AGS and SLE is presently unclear.
SAMHD1 contains a sterile alpha motif (SAM) and a motif of
cation-coordinating His and Asp residues (HD domain) that are
encountered in proteins with functions in nucleic acid meta-
bolism. Recently, SAMHD1 was demonstrated to restrict HIV-1
replication by hydrolyzing dNTPs to deoxynucleosides and
inorganic triphosphate in a deoxyguanosine triphosphate
(dGTP)-dependent fashion. This results in reduction of cellular
dNTP concentrations below the levels required for retroviral
reverse transcription (Hrecka et al., 2011; Laguette et al., 2011;
Lahouassa et al., 2012; Goldstone et al., 2011; Powell et al.,
2011; Kim et al., 2012). SAMHD1-mediated dNTP reduction is
operative in noncycling myeloid cells as well as in resting
T cells, and is at least partly responsible for the relative resistance
of dendritic cells and macrophages to HIV-1 infection (Baldauf
et al., 2012; Descours et al., 2012; Berger et al., 2011). The Vpx
accessory protein of many SIV strains and HIV-2 counteracts
this restriction by targeting SAMHD1 for proteasomal degrada-
tion (Hrecka et al., 2011; Laguette et al., 2011). The antiretroviral
activity is regulated by phosphorylation of SAMHD1 at Thr592
by Cyclin A2/CDK1 (Cribier et al., 2013; White et al., 2013b). In
addition to its deoxynucleotide hydrolase activity, SAMHD1
was recently shown to directly interact with nucleic acids and
to exhibit 30 exonuclease activity against RNA and DNA in vitro
(Beloglazova et al., 2013; Tu¨ngler et al., 2013).
Herein, we show that mouse SAMHD1, like the human
enzyme, decreases the dNTP pool in murine cells and restricts
retroviral infection. Importantly, we found that SAMHD1-defi-
cient mice display spontaneous type I IFN production and thus
model an important feature of AGS and SLE pathogenesis.690 Cell Reports 4, 689–696, August 29, 2013 ª2013 The AuthorsRESULTS
SAMHD1-Deficient Mice
Targeted embryonic stem cells (ESCs) carrying a gene trap
cassette inserted into intron1 of the SAMHD1 gene were used
to generate SAMHD1 knockout first (KOF) mice (Skarnes et al.,
2011; Figure S1). The gene trap cassette was spliced to exon1
as expected (Figure S1). A cryptic splice donor site 115 bp down-
stream of the gene trap splice acceptor was used to splice to
exon2 resulting in a frameshift and premature stops (Figure S1).
Low levels of the mutant sterile transcript could be detected,
whereas wild-type (WT) messenger RNA (mRNA) was absent in
SAMHD1KOF/KOF cells (Figure S1). A second SAMHD1-deficient
mouse strain, SAMHD1D/D, was generated by in vivo deletion
of the gene trap cassette and loxP-flanked exon2 (by Flpe-
and Cre-mediated recombination, respectively; Figure S1). In
SAMHD1D/D mice, a frameshift precludes gene expression.
Absence of SAMHD1 protein in SAMHD1KOF/KOF and
SAMHD1D/Dmicewas demonstrated bywestern blot (Figure S1).
SAMHD1KOF/KOF and SAMHD1D/D mice were obtained in Men-
delian ratios (not shown). Both strains were fertile and did not
feature macroscopic abnormalities.
Murine SAMHD1 Decreases Cellular dNTP
Concentrations and Restricts Retroviral Replication
Human SAMHD1 blocks HIV-1 replication in myeloid cells by
reducing the concentration of cellular dNTPs below the threshold
level required for reverse transcription (Hrecka et al., 2011; Lagu-
ette et al., 2011). To test whether murine SAMHD1 also deprives
cells of dNTPs, we compared dNTP levels in primary macro-
phages, bone-marrow-derived dendritic cells (BMDCs), splenic
B and T cells, and embryonic day 14.5 (E14.5) mouse embryonic
fibroblasts (MEFs) from SAMHD1D/D mice and littermate control
mice. In all cell types derived from SAMHD1-deficient mice,
the concentration of dNTPs was substantially higher than in WT
cells (Figure 1). Thus, murine SAMHD1 functions to reduce the
intracellular concentration of dNTPs.
Next,we sought to addresswhether SAMHD1-mediated dNTP
reduction results in restriction of retroviral replication in murine
cells and in mice in vivo. Therefore, we infected BMDCs from
SAMHD1-deficient and control mice with an HIV-1 reporter virus
in vitro. A single-cycleHIV-1 reporter virus basedon theHIV clone
NL4-3 (VSV-G/NL43-CMVGFP) was generated by transfection of
proviral DNA into 293T cells. Viral particles encoding a cytomeg-
alovirus (CMV) promotor-driven EGFP reporter gene were pseu-
dotyped with the glycoprotein of vesicular stomatitis virus
(VSV-G). Upon infection of the target cell, the viral RNA genome
is reverse transcribed and transported into the nucleus where
EGFP is expressed from integrated provirus. We found that
upon infection of murine BMDCs, the frequency of EGFP-ex-
pressing cells was5-fold higher in SAMHD1D/D cells compared
with control cells, as shown in Figure 2A,which represents a sum-
mary of two independent experiments. A third experiment based
on the same virus (Figure S2) and an additional experiment using
a different NL4-3-based reporter virus (VSV-G/HR.CMVGFP, not
shown) yielded similar results. To verify that the enhanced infec-
tion of SAMHD1D/D BMDCs was due to the absence of SAMHD1
activity, we complemented SAMHD1D/D cells by transduction
Figure 1. Murine SAMHD1 Functions to
Reduce Cellular dNTP Concentrations
An assay based on incorporation of a spe-
cific single nucleotide into a radiolabeled tem-
plate by RT was used to quantify the relative
amounts of each nucleotide in SAMHD1D/D
(KO) or control cells (WT). The indicated cell
types were flow-cytometrically sorted (except
for E14.5 MEFs), followed by extraction of
dNTPs, which were subsequently used as sub-
strates for the individual in vitro RT reactions. In a
second independent experiment, two dNTP ex-
tracts of pools from peritoneal macrophages and one pool from bone-marrow-derived macrophages from SAMHD1D/D or control cells yielded
similar results. Displayed are the means ± SD of two independent measurements, each performed in triplicate.with lentiviral particles encoding murine SAMHD1 or empty vec-
tor prior to infection with NL43-CMVGFP. In contrast to control
vector-transduced cells, we found that reconstituted SAMHD1
restoredHIV-1 restriction in otherwise permissive SAMHD1-defi-
cient BMDCs (Figure 2B). Infection of SAMHD1D/D and control
BMDCswith a third HIV reporter virus based on a different isolate
(HXB2) showedmoderateSAMHD1-mediated restriction in some
experiments, but not in others (not shown).
In order to address retroviral restriction by SAMHD1 also
in vivo, we infected SAMHD1-deficient and control mice with
an NL4-3-based VSV-G/HR.CMVGFP reporter virus by intrave-
nous injection and determined the frequencies of EGFP-
expressing cells 3 days later. As shown in Figure 2C, 4-fold
higher numbers of EGFP-expressing cells were detected in
SAMHD1-deficient versus control splenocytes. In a second,
independent experiment, the number of EGFP+ splenocytes
was 6-fold increased in mutant versus control mice (Figure 2D,
left panel). Differential analysis of the frequencies of EGFP+ cells
in individual splenic cell populations from these two experiments
revealed that SAMHD1-mediated retroviral restriction was oper-
ative in CD4+ and CD8+ T cells, B cells, dendritic cells, and
macrophages (Figures 2D and S2B). In contrast, the course of
in vivo infection with Friend virus (FV), a murine leukemia virus
(MLV), was not different in SAMHD1D/D versus control mice (Fig-
ure S2). We speculate that the replication of FV might not be
susceptible to restriction by SAMHD1 since the FV life cycle
requires cell division, whereas SAMHD1-mediated antiviral
activity seems to be limited to noncycling cells in which dNTP
pools are generally lower compared with cells in cycle (Baldauf
et al., 2012; Descours et al., 2012; Rampazzo et al., 2010). How-
ever, restriction of different MLVs by SAMHD1 was recently
reported in noncycling phorbol myristate acetate-differentiated
human U937 cells in vitro (White et al., 2013a, 2013b).
Collectively, our results show that mouse SAMHD1 reduces
cellular dNTP concentrations and inhibits retroviral replication.
The susceptibility to restriction by SAMHD1 differs among
different classes of retroviruses, and even different isolates of
the same virus may differ in their susceptibility to low dNTP
levels.
Spontaneous Type I IFN Release in SAMHD1-Deficient
Cells
Defects of two other AGS-associated enzymes, TREX1 and
ADAR1, result in spontaneous production of type I IFN in mice.To investigate whether loss of SAMHD1 also triggers activation
of an antiviral response in the mouse, we compared global
gene-expression profiles of cells from SAMHD1-deficient and
control mice. Because SAMHD1-mediated restriction was prom-
inent in myeloid cells, we chose to flow-cytometrically sort mac-
rophages from peritoneal lavage fluid (Figure S3). We performed
three independent experiments including a total of 25 SAMHD1-
deficient (SAMHD1D/D or SAMHD1KOF/KOF) and 19 control mice.
In the first experiment, RNA from tenmutant and ten control mice
was subjected to Illumina-based transcriptome sequencing
(RNA-Seq). We found that 141 genes were significantly (padj <
0.05) upregulated in SAMHD1-deficient compared with control
macrophages, and 123 (85%) of these were reported to be
inducible by type I IFN in the literature (Figure 3A; Table S1). A
second experiment (Figure S3) and a third experiment (not
shown) including a total of 15 mutant and nine control samples
yielded very similar results. Macrophages from an additional
cohort of ten SAMHD1-deficient mice that were also deficient
for the type I IFN receptor (SAMHD1KOF/KOFIFNAR1/ mice)
did not display the upregulation of IFN-inducible genes observed
in SAMHD1-deficient mice with intact type I IFN receptor.
Instead, SAMHD1KOF/KOFIFNAR1/ macrophages featured a
downregulation of IFN-inducible genes compared with WT con-
trol cells. Hasan et al. (2013) showed that the induction of anti-
viral genes in Trex1/ mice can occur in an IFN-independent
fashion in particular cell types. Our findings demonstrate that
the spontaneous transcriptional signature of antiviral genes in
SAMHD1-deficient macrophages is induced by type I IFN.
Hasan et al. (2013) did not observe a transcriptional signature
of IFN-inducible genes in fibroblasts from an AGS patient
carrying themutationSAMHD1R290H/Q548X, implying that sponta-
neous activation of IFN production may represent a cell-type-
specific phenomenon as suggested for TREX1 deficiency in
mice (Gall et al., 2012). In addition to Illumina-based transcrip-
tome profiling, we confirmed upregulation of five genes (Ifi44,
Pydc4, Oasl1, Rsad2, and Usp18) by quantitative RT-PCR
(qRT-PCR) of total RNA from fluorescence-activated cell sorting
(FACS)-purified peritoneal macrophages of eight additional
SAMHD1-deficient and 18 additional control mice. In all mutant
samples, levels of the five transcripts were increased compared
with the mean of controls (Figure 3B). Spontaneous upregulation
of IFN-inducible genes was also detected in SAMHD1-deficient
splenocytes and E14.5 MEFs compared with control cells (Fig-
ure 3C). Crossing SAMHD1D/D mice onto an IFN-b-deficientCell Reports 4, 689–696, August 29, 2013 ª2013 The Authors 691
Figure 2. Murine SAMHD1 Restricts Retro-
viral Replication
(A) BMDCs were generated from six mutant and
six control mice and infected with EGFP-con-
taining HIV-1-VSV-G (VSVG/NL43-CMVGFP).
Cellular EGFP fluorescence, indicating that the
virus had successfully reverse transcribed and
integrated its genome, was detected by FACS.
The graph represents a summary of two inde-
pendent experiments with similar results. A third
experiment with cells from three additional
mutant and three additional control mice yielded
similar results (Figure S2). Means ± SD are dis-
played.
(B) BMDCs from three SAMHD1-deficient mice
were transduced with a lentiviral vector carrying
either an EYFP and a murine SAMHD1 expression
cassette or only the EYFP cassette. After 48 hr,
the transduced cells were challenged with the
EGFP-expressing HIV-1 pseudotyped with VSV-G
(see A). EYFP+ cells were analyzed by FACS for EGFP expression 48 hr after challenge. Means ± SD are displayed.
(C) Five SAMHD1D/D and five SAMHD1WT/WT mice were injected intravenously with 1.8 3 107 particles of an EGFP-expressing HIV-1 pseudotyped with VSV-G
(VSVG/HR.CMVGFP) and two control mice (Ctrl, one SAMHD1D/D and one SAMHD1WT/WT) were injected with PBS. After 3 days, the mice were sacrificed and the
absolute numbers of live EGFP+ cells per 106 splenocytes were determined by flow cytometry. Means ± SD are displayed. Differential analysis of individual cell
populations from this experiment for HIV reporter infection is shown in Figure S2.
(D) Infection of five additional SAMHD1D/D and five additional WT mice with 53 106 particles of HIV reporter virus as in (C). Absolute numbers of live EGFP+ cells
in different splenic cell populations are shown. Means ± SD are displayed.
See also Figure S2.background (see Experimental Procedures) prevented sponta-
neous transcriptional activation of type I IFN-inducible genes,
as shown by qRT-PCR on three genes (Ifi44, Pydc4, and
Oasl1; Figure 3D). This demonstrates that IFN-b is indispensible
for the spontaneous activation of IFN-inducible genes in
SAMHD1-deficient mice and corroborates our findings in
SAMHD1-deficient IFNAR1/ macrophages.
DISCUSSION
Our findings thus indicate that an important function of SAMHD1
is to suppress spontaneous activation of the type I IFN system in
the steady state. AGS can be caused by defects in one of four
intracellular enzymes with functions in nucleic acid metabolism:
TREX1, RNase H2, ADAR1, and SAMHD1. AGS clinically over-
laps with SLE, and both diseases are associated with a sponta-
neous antiviral type I IFN response in the absence of detectable
exogenous virus infection. Intriguingly, TREX1 was reported to
have an impact on HIV infection by degrading nonproductive
by-products of reverse transcription (Yan et al., 2010). These
DNA fragments, although useless for HIV replication, can be
sensed by the infected cell and induce antiviral IFN responses.
Their degradation by TREX1 serves to hide HIV from the innate
immune system, preventing the IFN response. ADAR1 was
shown to promote retroviral replication in some studies (Phu-
phuakrat et al., 2008; Doria et al., 2009), but was described to
have antiretroviral activity in a recent report (Biswas et al.,
2012). SAMHD1 is an important HIV-1 restriction factor in non-
cycling human cells, which inhibits reverse transcription by
decreasing dNTP concentrations (Hrecka et al., 2011; Laguette
et al., 2011; Lahouassa et al., 2012;Goldstone et al., 2011; Powell
et al., 2011; Kim et al., 2012). Thus, defects of one of several692 Cell Reports 4, 689–696, August 29, 2013 ª2013 The Authorscellular enzymes that affect retroviral infection can cause human
autoimmune disease associated with uncontrolled type I IFN
responses. A causative link to an exogenous viral infection in
these conditions has not been established. The above findings
fuel the attractive hypothesis that AGS-associated enzymes are
important restriction factors for the activity of endogenous retro-
viruses and/or retrotransposons in the steady state. Loss of
these restriction factors may result in intracellular accumulation
of nucleic acids derived from these endogenous retroelements
and lead to their detection by intracellular nucleic acid sensors.
The ensuing cell-intrinsic innate antiviral response entails chronic
production of type I IFN, which in turn leads to autoimmunity.
Stetson et al. (2008) detected increased frequencies of retroele-
ment-encoded DNA sequences in the cytosol of Trex1/ cells,
providing evidence for enhanced activity of retroelements in the
absence of TREX1. Intriguingly, a combination of HIV-1 reverse
transcriptase (RT) inhibitors, which are also used to treat HIV
infection, significantly ameliorated the pathology of Trex1/
mice (Beck-Engeser et al., 2011). Rather than replication interme-
diates of endogenous retroelements, Yang et al. (2007) proposed
nucleic acids arising during replication of the cellular genome as
stimulators of the pathogenic IFN response in Trex1/ mice.
Knockoutmousemodels for TREX1 andADAR1 are both char-
acterized by lethal phenotypes, both of which are associated
with spontaneous production of type I IFN. The systemic autoim-
mune pathology of Trex1/ mice is reverted by additional
inactivation of the genes encoding interferon regulatory factor
3 (IRF3) or the type I IFN receptor, demonstrating the pivotal
role of the IFN response in the pathogenetic chain. Our findings
add SAMHD1 to the list of AGS-associated enzymes, defects
of which trigger spontaneous type I IFN production in themouse.
In contrast to Trex1/ and Adar1/ mice (Morita et al., 2004;
Figure 3. Spontaneous Induction of Type I IFN-Inducible Genes in
SAMHD1-Deficient Cells
(A) mRNA of FACS-sorted peritoneal macrophages from ten SAMHD1-defi-
cient, ten SAMHD1-deficient IFNAR1/, and ten control mice was analyzed
by Illumina-based transcriptome sequencing. In total, 37 genes were upre-
gulated at least 2-fold (p < 0.05) in SAMHD1-deficient mice compared with
controls. All but two of these genes were known to be inducible by type I IFN
(displayed as red dots). In the comparison of SAMHD1-deficient IFNAR1/
versus control cells, reduced transcript levels, rather than upregulation, were
observed for most of these genes (black dots).
(B) Transcript levels of five IFN-inducible genes found to be upregulated in the
transcriptome analysis (A) were quantified in peritoneal macrophages from
eight additional SAMHD1-deficient and 18 additional control mice by qRT-
PCR. Fold upregulation for individual mutant samples compared with the
mean of all control samples is displayed with colors identifying individual mice.
(C) Transcript levels of three IFN-inducible genes were assessed in SAMHD1-
deficient (n = 7) and control (n = 4) splenocytes, and in mutant (n = 5) and
control (n = 4) E14.5 MEFs by qRT-PCR. Results are displayed as fold change
for each mutant compared with the means of all controls. All genes were
significantly upregulated (p < 0.04) in all mutant samples analyzed.
(D) Transcript levels of three IFN-inducible genes in peritoneal macrophages
from SAMHD1D/D IFN-b-deficient (n = 8), SAMHD1D/D IFN-b competent (n = 8),
and SAMHD1WT/WT IFN-b-deficient (n = 8) mice as determined by qRT-PCR.
Results are displayed as fold change for each individual sample compared
with the mean of all WT control samples (n = 8).
See also Figure S3.Hartner et al., 2009), SAMHD1-deficient mice did not develop
detectable pathology or autoimmunity. The animals did not
develop macroscopic abnormalities up to the age of 70 weeks.
Histological analysis of tissues affected in AGS patients and
Trex1/mice, including heart, skin (Figure 4), lung, liver, kidney,
large arteries, skeletal muscle, skin, and brain (not shown), did
not reveal inflammatory changes in SAMHD1KOF/KOF (n = 13 [2
mice 16 weeks old, 11 older than 53 weeks]) or SAMHD1D/D
mice (n = 5 [3 mice 9–15 weeks old, 2 older than 43 weeks]).
Both AGS patients and Trex1/ mice show a high incidence
of antinuclear antibodies (ANAs) (Gall et al., 2012; Ramantani
et al., 2010). The incidence of ANAs in SAMHD1-deficient
mice, however, was not different from that in control C57BL/6
mice under the conditions of our animal facility, whereas ANAs
in titers above 1:320 (Figure 4), as well as lethal pathology (Fig-
ure S4), developed frequently in our cohort of Trex1/ animals
as expected.We speculate that levels of spontaneously released
type I IFN range below a threshold required for breakdown of
self-tolerance. Nevertheless, it seems likely that the activation
of the IFN response in SAMHD1-deficientmice reflects an impor-
tant pathogenic event of SAMHD1-associated AGS.
Our experiments did not address the question of cellular sour-
ces of type I IFN in SAMHD1-deficient mice. It will be important
to compare cell types that produce IFN in the various knockout
mouse models of AGS-associated enzymes. Moreover, the
innate sensors that trigger the spontaneous IFN response of
SAMHD1- and ADAR1-deficient cells remain unknown; how-
ever, the pathology of Trex1/ mice was demonstrated to
depend on the STING/TBK1/IRF3 pathway (Gall et al., 2012).
In conclusion, we have identified mouse SAMHD1 as a retro-
viral restriction factor that reduces cellular dNTP pools. More-
over, SAMHD1-deficient mice display a spontaneous activation
of the type I IFN system and thus reproduce an important feature
of AGS pathogenesis. SAMHD1 mutant mice may therefore be
instrumental in elucidating the mechanisms that trigger patho-
genic type I IFN responses in AGS and SLE.
EXPERIMENTAL PROCEDURES
Mice
Generation of SAMHD1-deficient mice was based on a targeted C57BL/6
JM8A3.N1 ESC clone (EPD0424_3_A06; http://www.knockoutmouse.org).
Mice deficient for IFN-b (Db-luc; Lienenklaus et al., 2009) were on the
C57BL/6 background. TREX1-deficient and IFNAR1/ mice (C57BL/6 back-
ground; Morita et al., 2004) were kindly provided by Thomas Lindahl (London
Research Institute, London, UK) and Ulrich Kalinke (TWINCORE, Hannover,
Germany), respectively. The mice were kept under specific pathogen-free
conditions at the Experimental Center of the University of Technology Dres-
den. All animal experiments were done according to institutional guidelines
on animal welfare and were approved by the Landesdirektion Dresden.
Immunofluorescence for Detection of ANA
3T3 cells were fixed on glass slides and incubated with diluted sera for 30 min.
Following two washes with PBS with 0.05% (v/v) Tween 20, slides were incu-
bated for 30 min in a 1:100 dilution of a sheep-anti-mouse-IgG-FITC antibody-
conjugate (Seramun Diagnostica) in PBS. After two washes, the slides were
covered with embedding media (Euroimmun AG) and analyzed.
dNTP Assay
A nucleotide incorporation assay was conducted as described previously
(Diamond et al., 2004).Cell Reports 4, 689–696, August 29, 2013 ª2013 The Authors 693
Figure 4. Spontaneous IFN Release Does
Not Result in Autoimmune Disease in
SAMHD1-Deficient Mice
(A) ANAs were detected by immunofluorescence
analysis on murine fibroblasts. The significance of
differences in ANA prevalence between groups
was tested by chi-square test (Pearson) with
Bonferroni correction. Autoantibodies occurred
more frequently in Trex1/ mice (n = 19, mean
age 10 weeks) compared with controls (Ctrl,
p < 0.0001, n = 38, mean age 15 weeks) or
SAMHD1-deficient mice (SAMHD1 KO, p < 0.005,
n = 15 [this group comprised SAMHD1KOF/KOF
and SAMHD1D/Dmice, mean age 20 weeks]). No significant increase in ANA frequencies could be detected in the SAMHD1-deficient versus the control group.
(B) Absence of inflammatory changes in heart and skin from SAMHD1-deficient mice. H&E-stained sections of heart and skin from oneWT, one SAMHD1KOF/KOF
animal, and one diseased Trex1/ animal from our facility, representative of 13 SAMHD1KOF/KOF mice analyzed (2 mice 16 weeks old, 11 older than 53 weeks)
and five SAMHD1D/D mice (3 mice 9–15 weeks old, 2 older than 43 weeks).
See also Figure S4.In Vitro and In Vivo HIV Reporter Virus Infection
For in vitro HIV-1 infection assays, 3.03 105 BMDCs fromSAMHD1D/D andWT
mice were infected with HIV-1-GFP at a multiplicity of infection (moi) = 1. The
number of infected cells was determined 3 days later by flow cytometry. For
SAMHD1-complementation assays, 1.0 3 105 BMDCs from SAMHD1D/D
mice were transduced with 50 ng p24 of SAMHD1-internal ribosome entry
site (IRES)-yellow fluorescent protein (YFP) viral vectors or control particles.
After 3 days, cells were infected with HIV-1-GFP at a moi = 1. The number
of infected cells was determined 3 days later by flow cytometry.
Mice were injected intravenously with 0.5 ml PBS or PBS containing 1.8 3
107 (first experiment) or 53 106 (second experiment) particles of pseudotyped
HIV-1 reporter virus (VSV-G/HR.CMVGFP; see above). After 3 days, the fre-
quencies of propidium iodide-negative EGFP+ cells in total splenocytes,
CD4+ and CD8+ T cells, B220+ B cells, CD11b+ CD11c+ dendritic cells, and
CD11b+ F4/80+ macrophages were analyzed by flow cytometry (antibodies
from eBioscience and BioLegend).
Sorting of Peritoneal Macrophages for Illumina-Based
Transcriptome Analysis
CD11b+ F4/80+ peritoneal macrophages (antibodies from eBioscience and
BioLegend, respectively) were flow-cytometrically sorted from peritoneal
lavage of SAMHD1D/D and WT mice, and lysed immediately in mMACS
mRNA Isolation Kit lysis buffer (Miltenyi Biotec).
Statistical Analysis
If not stated otherwise, data are shown asmeans ±SD. Statistical analysis was
performed using a Student’s t test (unpaired t test, two-tailed, 95% confidence
intervals). Significance levels in each figure are indicated by asterisks (*p %
0.05, **p < 0.01, ***p < 0.001).
For further details regarding the materials and methods used in this study,
see the Extended Experimental Procedures.
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